Media Release

COPENHAGEN, Denmark; April 17, 2023

GenmabA/S(Nasdaq:GMAB) andargenx(Euronext & Nasdaq:ARGX) announced today that Genmabandargenxhave entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas.Themultiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address unmet patient needs in immunology and cancer.

Genmabis entering the therapeutic area of immunologyand inflammationas asteppingstoneto achievingitsvision that by 2030, our knock-your-socks-offKYSOantibody medicines will be transforming the lives of people with cancer and other serious diseases, said Jan van de Winkel, Ph.D., Chief ExecutiveOfficer,Genmab. By partnering with argenx, we will be able to combine our deep knowledge of the biology and therapeutic power of antibodies and have an opportunity to address patients needs in oncology as well as in immunology and inflammation.

Our core mission is to innovate on behalf of patients by translating immunology breakthroughs into novel pipeline candidates. We do this through a model of co-creation which has led to eight molecules demonstrating human proof-of-concept in our pipeline, said Tim Van Hauwermeiren, Chief Executive Officer, argenx. Through our collaboration with Genmab, we are bringing together our combined antibody discovery, development and commercialization expertise to unlock insights on the disease pathways that we will address. This allows us to broaden our capabilities and maximize the opportunity to generate novel therapeutic antibodies within autoimmunity or cancer.

Collaboration DetailsAs per the agreement,argenxandGenmabwill each have access to the suites of proprietary antibody technologies of both companies to advance the identification of lead antibody candidates against differentiated disease targets. Under the terms of the agreement, argenx and Genmab will jointly discover, develop and commercialize products emerging from the collaboration while equally sharing costs as well as any potential future profits. The collaboration will initially focus on two differentiated targets, including one within immunology and one within cancer, with the potential to expand to more.

About Genmab Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmabs vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and- only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visitwww.argenx.comand follow us onLinkedIn,Twitter,andInstagram.

Genmab Contacts

Media

Jyoti Sharma, Director, Communications T: +1 609 480 9844; E: jysh@genmab.com

Investor Relations

Andrew Carlsen, Vice President, Head of Investor RelationsT: +45 3377 9558; E: acn@genmab.com

argenx Contacts

Media

Erin Murphyemurphy@argenx.com

Investors

Beth DelGiaccobdelgiacco@argenx.com

Genmab Forward-looking Statements This Media Release contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmabs most recent financial reports, which are available on http://www.genmab.com and the risk factors included in Genmabs most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at http://www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; DuoBody in combination with the DuoBody logo; HexaBody; HexaBody in combination with the HexaBody logo; DuoHexaBody and HexElect.

argenx Forward-looking StatementsThe contents of this announcement include statements that are, or may be deemed to be, forward- looking statements. These forward-looking statements can be identified by the use of forward- looking terminology, including the terms believes, hope, estimates, anticipates, expects, intends, may, will, or should and include statements argenx makes regarding the impact of the transitionof the chief operatingofficer; its launchstrategytomake VYVGARTavailable inthe EU, China, Canadaandselect otherregions;the VYVGARTmulti-dimensional expansionstrategy; its expansionthroughpotential regulatoryapprovals andlaunches and the planned launchof SC efgartigimod, ifapproved;the timingofdata readoutsandnew clinical efficacydata; theregulatory reviews andregulatoryapproval timinginthe United States,EU andJapan forSCefgartigimod forthe treatment ofgMG andthe long-term safety andtolerability ofSC efgartigimod; thetherapeutic potentialof itsproduct candidates; the intendedresults of itsstrategy andits collaborationpartners,advancement of, andanticipated clinical developmentandregulatorymilestonesandplans, including the timing of planned clinical trials; and the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature, forward-looking statements involverisksanduncertainties, andreadersarecautionedthatanysuchforward-lookingstatementsarenotguaranteesoffutureperformance.argenxsactualresultsmaydiffermateriallyfrom thosepredictedbytheforward-lookingstatementsasaresultofvariousimportantfactors, includingtheeffectsoftheCOVID-19pandemic,inflationanddeflationandthecorrespondingfluctuationsininterestrates;regionalinstabilityandconflicts,suchastheconflictbetweenRussiaandUkraine,argenxsexpectationsregardingtheinherentuncertainties associatedwithcompetitivedevelopments,preclinicalandclinicaltrialandproductdevelopmentactivitiesandregulatoryapprovalrequirements;argenxsrelianceoncollaborationswiththirdparties;estimatingthecommercialpotentialof argenxsproductcandidates;argenxsabilitytoobtainandmaintainprotectionofintellectualpropertyfor itstechnologiesanddrugs; argenxslimitedoperatinghistory;andargenxsabilitytoobtainadditionalfundingforoperationsandtocompletethedevelopmentandcommercializationofitsproductcandidates.Afurtherlistanddescriptionofthese risks, uncertainties andotherrisks canbe foundin argenxsU.S. Securities andExchange Commission(SEC)filings andreports, includingin argenxsmostrecent annual report onForm20-Ffiled with the SEC as well assubsequent filingsandreports filed byargenxwith theSEC.Giventhese uncertainties,the readeris advised not toplace any undue reliance onsuchforward-lookingstatements.Theseforward-lookingstatements speak onlyas ofthe dateof publicationof this document. argenx undertakesnoobligationto publicly update or revisethe informationinthis pressrelease, including any forward-looking statements, except as may be required by law.

Media Releaseno.04CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122

Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark

See more here:
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology - GlobeNewswire